Abstract:Background Fremanezumab, a humanized monoclonal antibody targeting calcitonin gene–related peptide (CGRP), is being investigated as a preventive treatment for migraine. We compared two fremanezumab dose regimens with placebo for the prevention of chronic migraine. Methods In this phase 3 trial, we randomly assigned patients with chronic migraine (defined as headache of any duration or severity on ≥15 days per month and migraine on ≥8 days per month) in a 1:1:1 ratio to receive fremanezumab quarterly (a single dose of 675 mg at baseline and placebo at weeks 4 and 8), fremanezumab monthly (675 mg at baseline and 225 mg at weeks 4 and 8), or matching placebo. Both fremanezumab and placebo were administered by means of subcutaneous injection. The primary end point was the mean change from baseline in the average number of headache days (defined as days in which headache pain lasted ≥4 consecutive hours and had a peak severity of at least a moderate level or days in which acute migraine–specific medication [triptans or ergots] was used to treat a headache of any severity or duration) per month during the 12 weeks after the first dose. Results Of 1130 patients enrolled, 376 were randomly assigned to fremanezumab quarterly, 379 to fremanezumab monthly, and 375 to placebo. The mean number of baseline headache days (as defined above) per month was 13.2, 12.8, and 13.3, respectively. The least-squares mean (±SE) reduction in the average number of headache days per month was 4.3±0.3 with fremanezumab quarterly, 4.6±0.3 with fremanezumab monthly, and 2.5±0.3 with placebo (P<0.001 for both comparisons with placebo). The percentage of patients with a reduction of at least 50% in the average number of headache days per month was 38% in the fremanezumab-quarterly group, 41% in the fremanezumab-monthly group, and 18% in the placebo group (P<0.001 for both comparisons with placebo). Abnormalities of hepatic function occurred in 5 patients in each fremanezumab group (1%) and 3 patients in the placebo group (<1%). Conclusions Fremanezumab as a preventive treatment for chronic migraine resulted in a lower frequency of headache than placebo in this 12-week trial. Injection-site reactions to the drug were common. The long-term durability and safety of fremanezumab require further study. (Funded by Teva Pharmaceuticals; ClinicalTrials.gov number, NCT02621931 .) Supported by Teva Pharmaceuticals. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. Dr. Silberstein reports receiving consulting fees from Alder BioPharmaceuticals, Allergan, Amgen, Automatic Technologies, Avanir Pharmaceuticals, Curelator, Depomed, Dr. Reddy’s Laboratories, electroCore, Eli Lilly, eNeura, Insys Therapeutics, Supernus Pharmaceuticals, Teva Pharmaceuticals, Theranica Bio-Electronics, and Trigemina; Dr. Dodick, receiving consulting fees from Acorda Therapeutics, Alder BioPharmaceuticals, Allergan, Amgen, Automatic Technologies, Biocentric, Biohaven, Boston Scientific, Charleston Laboratories, CoLucid Pharmaceuticals, Dr. Reddy’s Laboratories, Eli Lilly, eNeura, Insys Therapeutics, Ladenburg Thalmann, Magellan, Merck, Neuro Assessment Systems, Pfizer, Promius Pharma, Teva Pharmaceuticals, Tonix Pharmaceuticals, Trigemina, Xenon Pharmaceuticals, and Zosano Pharma, owning stock options in Epien Medical, Mobile Health, and Nocira, and serving on the board of King-Devick Test; Dr. Bigal, being an employee of Teva Pharmaceuticals; Dr. Yeung, being an employee of Teva Pharmaceuticals; Dr. Goadsby, receiving consulting fees from Akita Biomedical, Alder BioPharmaceuticals, Avanir Pharmaceuticals, Cipla, Dr. Reddy’s Laboratories, electroCore, Novartis, Pfizer, Quest Diagnostics, Scion Pharmaceuticals, and Teva Pharmaceuticals, receiving consulting fees and grant support from Allergan, Amgen, Eli Lilly, and eNeura, receiving consulting fees from and holding stock options in Trigemina, and holding a patent, licensed to eNeura, for “Methods and systems for preventative migraine headache treatment” (WO2016090333 A1); Ms. Blankenbiller, being an employee of Teva Pharmaceuticals; Ms. Grozinski-Wolff, being an employee of Teva Pharmaceuticals; Dr. Yang, being an employee of Teva Pharmaceuticals; Ms. Ma, being an employ -Abstract Truncated-

Assessing the Long-Term (48-Week) Effectiveness, Safety, and Tolerability of Fremanezumab in Migraine in Real Life: Insights from the Multicenter, Prospective, FRIEND3 Study

Early and sustained efficacy of fremanezumab over 24-weeks in migraine patients with multiple preventive treatment failures: the multicenter, prospective, real-life FRIEND2 study

Menopause and its impact on the effectiveness of fremanezumab for migraine prophylaxis: post-hoc analysis of a prospective, real-world Greek registry

Long-Term Effectiveness of Three Anti-CGRP Monoclonal Antibodies in Resistant Chronic Migraine Patients Based on the MIDAS score

Fremanezumab for the Preventive Treatment of Chronic Migraine

Long-Term Effectiveness of Galcanezumab in the Prevention of Migraine: An Italian Retrospective Analysis (REALITY)

Reversion of chronic to episodic migraine in working age and botulinum toxin-resistant patients treated with fremanezumab: A real-life study

Real-world effectiveness of fremanezumab in patients with migraine switching from another mAb targeting the CGRP pathway: a subgroup analysis of the Finesse Study

Retrospective Observational Study on 209 Patients

Nine-Month Continuous Fremanezumab Prophylaxis on the Response to Triptans and Also on the Incidence of Triggers, Hypersensitivity and Prodromal Symptoms of Patients with High-Frequency Episodic Migraine

Long‐term efficacy and safety of erenumab in migraine prevention: Results from a 5‐year, open‐label treatment phase of a randomized clinical trial

Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study

Anti‑CGRP monoclonal antibodies in resistant migraine: preliminary real-world effectiveness and clinical predictors of response at two years

Effects of fremanezumab on migraine-associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double-blind, placebo-controlled trial

Real-world long-term efficacy and safety of erenumab in adults with chronic migraine: a 52-week, single-center, prospective, observational study

No wearing-off effect of erenumab or fremanezumab for chronic migraine prevention: a single-center, real-world, observational study

The effect of erenumab on brain network function in episodic migraine patients: a randomized, placebo-controlled clinical trial (RESET BRAIN)

A Dutch cost-effectiveness analysis of fremanezumab versus best supportive care in patients with chronic migraine and inadequate response to prior preventive therapy

A multicenter, open-label, phase 3 study to evaluate the safety of fremanezumab for migraine, subcutaneously self-administered with an auto-injection device at institutional sites and at home

Redefining migraine prevention: early treatment with anti-CGRP monoclonal antibodies enhances response in the real world

Beyond Pain Relief: Unveiling the Multifaceted Impact of Anti-CGRP/R mAbs on Comorbid Symptoms in Resistant Migraine Patients